Neogen Corporation (NEOG) vs Supernus Pharmaceuticals, Inc. (SUPN)
A side-by-side comparison of Neogen Corporation and Supernus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NEOG
Neogen Corporation
$11.88HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
SUPN
Supernus Pharmaceuticals, Inc.
$42.57HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
Total return — NEOG vs SUPN
growth of $100 · dividends reinvested · last 10yNEOG -37.4% (-4.6%/yr)SUPN +79.4% (+6.0%/yr)SUPN compounded faster over this window
NEOG SUPN
NEOG vs SUPN: by the numbers
- •NEOG is the larger company ($2.59B vs $2.47B market cap).
- •Both run net losses; NEOG's is the smaller (-0.91% vs -13.23% net margin).
- •NEOG grew revenue faster over the past five years (13.19% vs 7.78% CAGR).
Metrics side by side
Valuation
| Metric | NEOG | SUPN |
|---|---|---|
| Forward P/E | 38.32 | 16.60 |
| P/S ratio | 2.98 | 2.98 |
| P/B ratio | 1.24 | 2.40 |
| EV / EBITDA | 31.91 | N/A |
| FCF yield | N/A | 0.76% |
Profitability
| Metric | NEOG | SUPN |
|---|---|---|
| Gross margin | 46.93% | 88.07% |
| Operating margin | -2.49% | -5.13% |
| Net margin | -0.91% | -13.23% |
| ROE | -0.38% | -10.66% |
| ROIC | -0.68% | -10.24% |
Growth (annualized)
| Metric | NEOG | SUPN |
|---|---|---|
| Revenue CAGR (5Y) | 13.19% | 7.78% |
| FCF CAGR (5Y) | N/A | -30.77% |
| Total return CAGR (5Y) | -21.13% | 9.85% |
Frequently asked
- Which has grown faster, NEOG or SUPN?
- Over the past five years, NEOG grew revenue faster — NEOG at a 13.19% CAGR versus SUPN at 7.78%.
- How have NEOG and SUPN total returns compared?
- Over the past 10 years, NEOG delivered -4.56% and SUPN delivered 5.87% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.